IPO
Neos Therapeutics, Inc. today announced the pricing of an underwritten public offering of 17,391,304 shares of its common stock at a price to the public of $2.30 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Neos.
Neos Therapeutics, Inc. today announced that it has commenced an underwritten public offering of its common stock
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Product and Service revenue up 29% year-on-year
OptiBiotix Health has named Adam Reynolds as Non-Executive Chairman of its new specialist probiotic subsidiary ProBiotix Health Limited. With 14 commercial deals in just under 18 months and a strong deal pipeline in place ProBiotix is well placed to become a stand-alone company.
PhaseBio Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 9,200,000 shares of common stock at a price to the public of $5.00 per share, for total gross proceeds of approximately $46.0 million.
PRESS RELEASES